No profile data available.
Cabaletta Bio, Inc. (CABA) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Philadelphia, United States, with about 154 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$167.86 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $327.22 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Cabaletta Bio reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$327.22 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Shattuck Labs, Inc. (STTK), Kyverna Therapeutics, Inc. (KYTX), Zura Bio Limited (ZURA), Century Therapeutics, Inc. (IPSC).